TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07918469: A Phase 1, Single Center, Open-Label, Single Ascending Dose and Multiple Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral Cannabidiol Capsules (AVAT-121) and Epidyolex® in Healthy Male and Femal

Sponsor: Avata Biosciences Holdings Ltd · Phase: PHASE1 · Area: CNS_NEUROLOGY · Target Enrollment: 44 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$8,442,880

Rescue Site Savings

+$5,567,024

Unlock Full NCT07918469 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07918469 Rescue Dossier →